Christina (Tina) P./LinkedIn
Sep 14, 2026, 04:43
Christina (Tina) P.: Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis
Christina (Tina) P., CEO and Co-Founder of APS Foundation of America, shared on LinkedIn:
“Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis
Eye damage remains uncommon after 15 years, but certain factors increase the risk by John Gever, Contributing Writer, MedPage Today.
A recent meta-analysis details that the risk of retinopathy from long-term hydroxychloroquine (HCQ) treatment remains low initially but increases significantly after decades of continuous use.
Clinical guidelines recommend baseline eye exams and annual ophthalmologic screenings after five years of use to prevent permanent vision loss.
More posts featuring Christina (Tina) P. on Hemostasis Today.
-
Sep 14, 2026, 15:53Leonard Valentino: Advancing a New Model of Patient-Led Research
-
Sep 14, 2026, 15:48Adishwar Rao: LAAC vs Oral Anticoagulation in Atrial Fibrillation
-
Sep 14, 2026, 15:36Lesley Van Wyk: Hemolytic Anemia Quick Revision – Tips and Tricks
-
Sep 14, 2026, 15:35Maha Othman: ISTH-BAT Reference Ranges Validated Across Five Continents in Children
-
Sep 14, 2026, 15:30Umberto Pensato։ Left Ventricular Dysfunction and DOAC Benefit in ESUS
-
Sep 14, 2026, 15:22Meral Kayikcioglu: Why Do Women and Men Differ in LDL-C Management?
-
Sep 14, 2026, 15:22James Crowley: The Complex Role of CRP in Cardiovascular Risk and Atherosclerosis
-
Sep 14, 2026, 15:16Factor XIII Deficiency An Often-Missed Bleeding Disorder
-
Sep 14, 2026, 15:07Raffaele Piccolo: Heparin Against Jellyfish Venom?